Johnson & Johnson (NYSE:JNJ) has discontinued a combination therapy involving its experimental antibody therapy, nipocalimab, for rheumatoid arthritis after a failure in a mid-stage trial, which evaluated it against treatments such as AbbVie’s (NYSE:ABBV) blockbuster Humira.
The decision was based